_
Applied Biosystems' TaqMan(R) Genomic Assays to Be Included in GeneCards(R)
"FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 5, 2005--Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, and Xennex, Inc., the exclusive provider of commercial licenses for the GeneCards(R) database of human genes, today announced an agreement whereby Applied Biosystems TaqMan(R) Genomic Assays will be accessible via GeneCards. Under the terms of agreement, Applied Biosystems will provide GeneCards customers direct access to its entire collection of nearly three million genomic assays.
"With access to Applied Biosystems TaqMan(R) Genomic Assays and relevant links to other databases of human genes, the information contained in GeneCards is particularly useful for researchers looking for information about genes of interest in the context of functional genomics and genetic variation," said William V. Murray, Division President of Molecular Biology for Applied Biosystems. "Our three million ready-to-order assays available for gene expression and SNP genotyping studies will allow researchers to quickly advance their gene expression studies, as well as SNP screening, association, candidate region, candidate gene, or fine-mapping studies directly from GeneCards."
GeneCards is a popular searchable database of human genes and their encoded proteins, with major focus on functional genomics and medical aspects including involvement in diseases. GeneCards offers concise information about the structure and function of human genes. It extracts and integrates a carefully selected subset of the gene information, obtained from major data sources, public and proprietary, successfully overcoming barriers of data format heterogeneity.
GeneCards was developed over the last eight years at the Weizmann Institute of Science in Israel under the direction of Professor Doron Lancet, Head of the Institute's Crown Human Genome Center. More information on GeneCards can be found at http://bioinfo.weizmann.ac.il/genecards/.
"GeneCards users are continually looking for ways to find information of value on specific genes and link to resources that will move their research forward," said David Warshawsky, Ph.D., Chief Executive Officer of Xennex, Inc. "Offering access to Applied Biosystems assay products allows us to provide our commercial and academic users innovative tools that will quickly help them follow promising database search leads with real-world lab experiments."
The Applied Biosystems TaqMan Assays product line includes more than 600,000 gene-specific probe and primer sets for quantitative gene expression studies of human, mouse, rat, Arabidopsis, Drosophila (fruit fly), and more than two million human SNP assays for genome-wide marker coverage. The assays run on Applied Biosystems Real-Time PCR systems, including the 7300, 7500, and 7900HT Systems.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2003. The Celera Genomics Group (NYSE:CRA), located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics. Its Celera Discovery System(TM) online platform, marketed exclusively by Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
About Xennex
Xennex, Inc. (www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex operations worldwide are carried out from its offices in Massachusetts, USA. Xennex' customers include many of the world leading biotech and pharmaceutical companies, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by thousands of users around the globe.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "plans," and "should" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) Applied Biosystems' dependence on the operation of computer hardware, software, and Internet applications and related technology; (4) unproven use of genomics information to develop or commercialize products; and (5) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Copyright(C) 2004. Applera Corporation. All rights reserved. Applied Biosystems is a registered trademark and Applera, Assays-on-Demand, Celera, Celera Diagnostics, Celera Discovery System, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc. GeneCards is a registered trademark of Yeda Research and Development Co. Ltd.
For Research Use Only. Not for use in diagnostic procedures."
Source: Applied Biosystems' TaqMan(R) Genomic Assays to Be Included in GeneCards(R). Businesswire.com (5 July 2005)[FullText]
"With access to Applied Biosystems TaqMan(R) Genomic Assays and relevant links to other databases of human genes, the information contained in GeneCards is particularly useful for researchers looking for information about genes of interest in the context of functional genomics and genetic variation," said William V. Murray, Division President of Molecular Biology for Applied Biosystems. "Our three million ready-to-order assays available for gene expression and SNP genotyping studies will allow researchers to quickly advance their gene expression studies, as well as SNP screening, association, candidate region, candidate gene, or fine-mapping studies directly from GeneCards."
GeneCards is a popular searchable database of human genes and their encoded proteins, with major focus on functional genomics and medical aspects including involvement in diseases. GeneCards offers concise information about the structure and function of human genes. It extracts and integrates a carefully selected subset of the gene information, obtained from major data sources, public and proprietary, successfully overcoming barriers of data format heterogeneity.
GeneCards was developed over the last eight years at the Weizmann Institute of Science in Israel under the direction of Professor Doron Lancet, Head of the Institute's Crown Human Genome Center. More information on GeneCards can be found at http://bioinfo.weizmann.ac.il/genecards/.
"GeneCards users are continually looking for ways to find information of value on specific genes and link to resources that will move their research forward," said David Warshawsky, Ph.D., Chief Executive Officer of Xennex, Inc. "Offering access to Applied Biosystems assay products allows us to provide our commercial and academic users innovative tools that will quickly help them follow promising database search leads with real-world lab experiments."
The Applied Biosystems TaqMan Assays product line includes more than 600,000 gene-specific probe and primer sets for quantitative gene expression studies of human, mouse, rat, Arabidopsis, Drosophila (fruit fly), and more than two million human SNP assays for genome-wide marker coverage. The assays run on Applied Biosystems Real-Time PCR systems, including the 7300, 7500, and 7900HT Systems.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2003. The Celera Genomics Group (NYSE:CRA), located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop new therapeutics. Its Celera Discovery System(TM) online platform, marketed exclusively by Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
About Xennex
Xennex, Inc. (www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex operations worldwide are carried out from its offices in Massachusetts, USA. Xennex' customers include many of the world leading biotech and pharmaceutical companies, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by thousands of users around the globe.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "plans," and "should" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) Applied Biosystems' dependence on the operation of computer hardware, software, and Internet applications and related technology; (4) unproven use of genomics information to develop or commercialize products; and (5) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Copyright(C) 2004. Applera Corporation. All rights reserved. Applied Biosystems is a registered trademark and Applera, Assays-on-Demand, Celera, Celera Diagnostics, Celera Discovery System, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc. GeneCards is a registered trademark of Yeda Research and Development Co. Ltd.
For Research Use Only. Not for use in diagnostic procedures."
Source: Applied Biosystems' TaqMan(R) Genomic Assays to Be Included in GeneCards(R). Businesswire.com (5 July 2005)[FullText]
posted by BioMedMarket.Info @ 6.7.05
0 Comments:
Post a Comment
<< Home